<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875185</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00079522</org_study_id>
    <nct_id>NCT01875185</nct_id>
  </id_info>
  <brief_title>Hormones Inflammation and Thrombosis</brief_title>
  <acronym>HIT2</acronym>
  <official_title>Hormones Inflammation and Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are attempting to determine if the response to aspirin in women is related
      to the level of estrogen and progesterone that a woman has.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombosis plays a significant role in both acute coronary syndromes (ACS) and early
      saphenous vein graft (SVG) failure. Women with coronary heart disease have higher levels of
      the inflammatory mediator thromboxane, which is produced by platelets, monocytes, macrophages
      and the endothelium. Data show that higher levels of urinary thromboxane (UTXB2) are
      associated with SVG failure 6 months after Coronary Artery Bypass Graft (CABG). Women in the
      study cohort had higher levels of UTXB2 and higher odds of graft failure when compared to
      men. The elevated urinary thromboxane seen in the women in our study cohort may represent a
      marker and/or an etiology of thrombosis.

      Are the levels of UTXB2 higher in women due to hormonal differences? In a prior pilot study
      we investigated whether hormonal levels are associated with changes in urinary thromboxane.
      We looked at hormonal and urinary thromboxane levels in 48 postmenopausal and 52
      premenopausal women. We found that postmenopausal women had higher levels of UTXB2 than did
      premenopausal women (2495 vs. 2299, p=.02) and that in premenopausal women a higher
      estrogen/progesterone ratio was associated with the highest levels of urinary thromboxane.

      The goal of the current study is to measure the response to seven days of aspirin
      administration as it relates to urinary thromboxane levels in pre and post-menopausal women.
      With this study we will be able to examine the change in UTXB2 comparing the premenopausal to
      post menopausal women. We will also be able to see if the change in UTXB2 in response to
      aspirin is affected by hormone levels in the premenopausal women. Lastly this study will
      provide reference data for more far-reaching studies exploring how global changes in hormonal
      balance (as seen in pregnancy or menopause) or in the level of inflammation (as seen in aging
      or with Coronary Artery Disease (CAD) risk factors), affect UTXB2 and platelet
      hyperreactivity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funds for specimen management and data analysis
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Urinary Thromboxane (UTXB2) in pg/mg Creatinine</measure>
    <time_frame>Baseline</time_frame>
    <description>Urinary thromboxane (pg/mg creatinine) will be measured in premenopausal and postmenopausal women at baseline and then after taking on aspirin for 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in the Level of UTXB2 in pg/mg Creatinine: Estrogen and Progesterone</measure>
    <time_frame>baseline to 7 days</time_frame>
    <description>Measurement of urinary thromboxane (pg/mg creatinine) in relation to estrogen to progesterone level in premenopausal women on aspirin for 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of UTXB2 in pg/mg Creatinine</measure>
    <time_frame>baseline</time_frame>
    <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change of UTXB2 in pg/mg Creatinine in Response to Aspirin</measure>
    <time_frame>change from baseline to 7 days</time_frame>
    <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients are given aspirin 81 mg orally for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Aspirin 81 mg orally daily for 7 days</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age 18-80

          2. Signed informed consent.

        Exclusion Criteria:

          1. History of CAD, Cerebrovascular Accident (CVA) or Peripheral Artery Disease (PAD),

          2. On chronic aspirin therapy,

          3. On chronic NSAID therapy.

          4. Chronic anticoagulation with coumadin,

          5. Known thrombocytopenia (Platelet count &lt; 100,000),

          6. Pregnancy (self-report),

          7. Currently on any type of contraceptive or hormone replacement therapy,

          8. Hysterectomy and/or oophorectomy.

          9. Recent GI bleeding

         10. Bleeding diathesis

         11. Chronic Systemic Infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rhondalyn McLean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>August 15, 2017</results_first_submitted>
  <results_first_submitted_qc>April 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2018</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>clotting</keyword>
  <keyword>hormones</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Premenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
        <group group_id="P2">
          <title>Postmenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study was terminated</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Premenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
        <group group_id="B2">
          <title>Postmenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Urinary Thromboxane (UTXB2) in pg/mg Creatinine</title>
        <description>Urinary thromboxane (pg/mg creatinine) will be measured in premenopausal and postmenopausal women at baseline and then after taking on aspirin for 7 days.</description>
        <time_frame>Baseline</time_frame>
        <population>Data was only collected at baseline. The study was terminated prior to initiation of intervention (Aspirin) and therefore no follow-up data was collected to calculate the change from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Premenopausal</title>
            <description>premenopausal Women in the cohort</description>
          </group>
          <group group_id="O2">
            <title>Postmenopausal</title>
            <description>Postmenopausal Women in the cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Urinary Thromboxane (UTXB2) in pg/mg Creatinine</title>
          <description>Urinary thromboxane (pg/mg creatinine) will be measured in premenopausal and postmenopausal women at baseline and then after taking on aspirin for 7 days.</description>
          <population>Data was only collected at baseline. The study was terminated prior to initiation of intervention (Aspirin) and therefore no follow-up data was collected to calculate the change from baseline.</population>
          <units>pg/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2495" lower_limit="1775" upper_limit="3053"/>
                    <measurement group_id="O2" value="2299" lower_limit="1724" upper_limit="2687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in the Level of UTXB2 in pg/mg Creatinine: Estrogen and Progesterone</title>
        <description>Measurement of urinary thromboxane (pg/mg creatinine) in relation to estrogen to progesterone level in premenopausal women on aspirin for 7 days.</description>
        <time_frame>baseline to 7 days</time_frame>
        <population>Data was only collected at baseline. The study was terminated prior to obtaining study data.</population>
        <group_list>
          <group group_id="O1">
            <title>Premenopausal</title>
            <description>Aspirin 81 mg PO daily x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Postmenopausal</title>
            <description>Aspirin 81 mg PO daily x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in the Level of UTXB2 in pg/mg Creatinine: Estrogen and Progesterone</title>
          <description>Measurement of urinary thromboxane (pg/mg creatinine) in relation to estrogen to progesterone level in premenopausal women on aspirin for 7 days.</description>
          <population>Data was only collected at baseline. The study was terminated prior to obtaining study data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of UTXB2 in pg/mg Creatinine</title>
        <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
        <time_frame>baseline</time_frame>
        <population>Data was only collected at baseline. The study was terminated prior to initiation of intervention (Aspirin) and therefore no follow-up data was collected to calculate the change from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Premenopausal</title>
            <description>Premenopausal females in the cohort Aspirin 81 mg PO daily x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Postmenopausal</title>
            <description>Postmenopausal females in the cohort Aspirin 81 mg PO daily x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Level of UTXB2 in pg/mg Creatinine</title>
          <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
          <population>Data was only collected at baseline. The study was terminated prior to initiation of intervention (Aspirin) and therefore no follow-up data was collected to calculate the change from baseline.</population>
          <units>pg/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2299" lower_limit="1724" upper_limit="2687"/>
                    <measurement group_id="O2" value="2824" lower_limit="2198" upper_limit="3252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change of UTXB2 in pg/mg Creatinine in Response to Aspirin</title>
        <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
        <time_frame>change from baseline to 7 days</time_frame>
        <population>No data was collected for this outcome measure, as the study was terminated prematurely</population>
        <group_list>
          <group group_id="O1">
            <title>Premenopausal</title>
            <description>Premenopausal females in the cohort Aspirin 81 mg PO daily x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Postmenopausal</title>
            <description>Postmenopausal females in the cohort Aspirin 81 mg PO daily x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change of UTXB2 in pg/mg Creatinine in Response to Aspirin</title>
          <description>Comparing premenopausal women to postmenopausal women, the level of urinary thromboxane (pg/mg creatinine) in response to aspirin</description>
          <population>No data was collected for this outcome measure, as the study was terminated prematurely</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Premenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Postmenopausal</title>
          <description>Aspirin 81 mg PO daily x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>RhondaLyn McLean</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>(215) 662-4949</phone>
      <email>rhondalyn.mclean@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

